Companion diagnostic technologies market seen hitting $7.89 billion by 2030

The Business Research Company says the companion diagnostic technologies market will grow from $4.97 billion in 2026 to $7.89 billion by 2030, driven by precision medicine, targeted therapies and broader use of AI and liquid biopsy tools. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Companion diagnostics help match patients to the treatments most likely to work, which is central to precision medicine. - The market’s growth reflects rising demand for targeted therapies, cancer care tools and biomarker-based testing. - The projected expansion signals more spending on tests that can improve treatment choice and reduce side effects.

What happened: - The Business Research Company projected the companion diagnostic technologies market will grow from $4.97 billion in 2026 to $7.89 billion by 2030. - The forecast implies a 12.2% compound annual growth rate through 2030. - The company said the market was worth $4.44 billion in 2025. - The release was published June 23, 2026. - The company made a free sample of the market report available. - The company also pointed readers to the full market report.

The details: - Companion diagnostic technologies are tests and tools designed to detect biomarkers that predict how a patient will respond to a specific treatment. - The diagnostics are used to help select targeted therapies based on a patient’s molecular or genetic profile. - The report said historical growth was driven by precision medicine adoption, rising cancer and chronic disease cases, demand for targeted treatments, more molecular diagnostics research and higher biomarker discovery investment. - Future growth is expected to come from personalized therapy development, AI-powered diagnostic interpretation, noninvasive liquid biopsy tests, pharma-diagnostic collaboration and more regulatory approvals for companion diagnostic assays. - Trends highlighted in the report include biomarker-driven therapy selection, next-generation sequencing diagnostics, liquid biopsy adoption, personalized oncology and multiplex molecular diagnostic testing. - Targeted therapies are treatments that identify and attack cancer cells or molecular targets while sparing healthy tissue. - Companion diagnostics support that process by identifying genetic mutations, biomarkers and molecular characteristics that guide therapy selection. - The report cited an American Society of Gene & Cell Therapy update showing gene therapies in Phase II trials rose from 247 at the end of Q1 2023 to 260 at the end of Q2 2023, a 5% increase. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow fastest during the forecast period. - The regional analysis also covered South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report suite includes market attractiveness scoring, TAM analysis, a company scoring matrix, Excel dashboards, market hotspot infographics, key technology analysis and future trend analysis.

Between the lines: - The forecast suggests companion diagnostics are moving from a supporting role to a larger commercial pillar of personalized medicine. - The emphasis on AI, liquid biopsy and sequencing shows the market is shifting toward faster and less invasive testing. - The Asia-Pacific growth outlook points to rising demand beyond the U.S. and Europe as healthcare systems expand precision medicine adoption.

What's next: - More regulatory approvals for companion diagnostic assays could further expand the market. - Partnerships between pharmaceutical and diagnostic companies are likely to remain a key growth driver. - Continued uptake of biomarker-guided oncology testing should keep companion diagnostics tied closely to the targeted-therapy pipeline.

The bottom line: - Companion diagnostic technologies are on track for steady double-digit growth as precision medicine becomes more mainstream.